Enfuvirtide, ENF, T-20, Fuzeon, DP-178

General Information


DRACP ID  DRACP03511

Peptide Name   Enfuvirtide, ENF, T-20, Fuzeon, DP-178

Sequence  YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF

Sequence Length  36

UniProt ID  P04578 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  DRACP03511

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C202H298N50O64

Absent amino acids  CGMPRV

Common amino acids  EL

Mass  507536

Pl  4.02

Basic residues  3

Acidic residues  7

Hydrophobic residues  13

Net charge  -4

Boman Index  -7259

Hydrophobicity  -87.5

Aliphatic Index  89.44

Half Life 
  Mammalian: 2.8 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  17990

Absorbance 280nm  514

Polar residues  9

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30716118

Title  Monotherapy With a Low-Dose Lipopeptide HIV Fusion Inhibitor Maintains Long-Term Viral Suppression in Rhesus Macaques

Doi Not available

Year  2019

Literature 2

Pubmed ID 30867304

Title  Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors With Extremely Potent and Long-Lasting Antiviral Activity

Doi Not available

Year  2019

Literature 3

Pubmed ID 31228294

Title  Optimization of Peptidic HIV-1 Fusion Inhibitor T20 by Phage Display

Doi Not available

Year  2019

Literature 4

Pubmed ID 31805154

Title  IgG Fc-binding Motif-Conjugated HIV-1 Fusion Inhibitor Exhibits Improved Potency and in Vivo Half-Life: Potential Application in Combination With Broad Neutralizing Antibodies

Doi Not available

Year  2019

Literature 5

Pubmed ID 31932193

Title  Suitable Fusion of N-terminal Heptad Repeats to Achieve Covalently Stabilized Potent N-peptide Inhibitors of HIV-1 Infection

Doi Not available

Year  2020

Literature 6

Pubmed ID 27795416

Title  Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors

Doi Not available

Year  2016

Literature 7

Pubmed ID 19073606

Title  Design of peptide-based inhibitors for human immunodef

Doi 

Year 

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  6056

DRACP is developed by Dr.Zheng's team.